Apnimed Releases More Data on Its Leading Sleep Apnea Drug Candidate
At CHEST, the company released additional data from its pivotal phase 3 SynAIRgy and LunAIRo trials evaluating the investigational drug, AD109.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
